Post Marketing Study on Pluvicto in Korea

计划入组 278 人 · 首次发布于 2024 年 7 月 23 日

Pluvicto Real-world Investigation in Survival in Metastatic CRPC

计划入组 1,085 人 · 首次发布于 2026 年 7 月 13 日

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

计划入组 60 人 · 首次发布于 2025 年 7 月 31 日

Lutetium Lu-177 vipivotide tetraxetan(Pluvicto)

C₄₉H₆₈LuN₉O₁₆

Carilion Clinic and FBRI Expand Theranostics Clinical Trials, Positioning Southwest Virginia as a Hub for Targeted Radiopharmaceutical Cancer Therapies

Pluvicto Demonstrates Significant Radiographic Progression-Free Survival Benefit in PSMA-Positive mCRPC

FDA Expands Pluvicto Approval for Earlier Treatment of Metastatic Prostate Cancer